The agreement with the FDA is a critical regulatory milestone for Helius Medical Technologies, indicating a positive outlook for the company's stroke treatment program. This development is likely to be viewed favorably by investors, as it not only demonstrates the company's ability to navigate regulatory pathways but also brings it closer to market entry. Given the significant impact of strokes and the demand for innovative treatments, this news could positively influence the company's stock price in the short term.